中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
9期
1246-1248
,共3页
α硫辛酸%糖尿病肾病%氧化应激
α硫辛痠%糖尿病腎病%氧化應激
α류신산%당뇨병신병%양화응격
Alpha-lipoic acid%Diabetic nephropathy%Oxidative stress
目的 观察抗氧化剂α硫辛酸对早期糖尿病肾病患者氧化应激水平的影响及对肾脏的保护作用.方法 采用随机数字表将80例早期糖尿病肾病患者随机分为观察组(40例)和对照组(40例),另从门诊体检中心选择30例健康人为健康组.对照组给予常规治疗；观察组在常规治疗的基础上加用α硫辛酸0.6 g/次,1次/d静脉滴注,疗程3周；健康组不采取任何治疗.分别测定观察组和对照组治疗前后及健康组丙二醛(MDA)、血清晚期蛋白氧化产物(AOPPs)、血浆超氧化物歧化酶(SOD)和24h尿白蛋白排泄率(UAER).结果 对照组和观察组治疗前较健康组血浆MDA[(5.8 ±2.1)、(5.6±2.3) μmol/L比(3.8±0.9) μmol/L]、AOPPs[(69.4±10.9)、(69.2±11.1) μmol/L比(22.6±2.9) μmol/L]、24 h UAER[(274±33),(270±46) mg/24 h比(12 ±4) mg/24 h]明显升高,SOD[(47±4)、(47±4)U/ml比(74±4) U/ml]较健康组明显降低,差异均有统计学意义(均P＜0.05).对照组治疗3周后MDA、AOPPs、SOD、24 h UAER与治疗前比较差异无统计学意义(P＞0.05)；观察组治疗后MDA、AOPPs、24h UAER较治疗前下降[分别为:MDA为(2.7±1.9) μmol/L比(5.6±2.3) μmol/L,AOPPs为(61.7±12.6)μmol/L比(69.2±11.1) μmol/L],24 h UAER为(183±42) mg/24 h比(270±46) mg/24 h,SOD较治疗前[(52±4)U/ml比(47±4) U/ml]升高,治疗后各指标与治疗前比较差异有统计学意义(P＜0.05).结论 氧化应激在糖尿病肾病的发生发展中起重要作用.α硫辛酸能降低糖尿病患者氧化应激水平,延缓糖尿病肾病进展.
目的 觀察抗氧化劑α硫辛痠對早期糖尿病腎病患者氧化應激水平的影響及對腎髒的保護作用.方法 採用隨機數字錶將80例早期糖尿病腎病患者隨機分為觀察組(40例)和對照組(40例),另從門診體檢中心選擇30例健康人為健康組.對照組給予常規治療；觀察組在常規治療的基礎上加用α硫辛痠0.6 g/次,1次/d靜脈滴註,療程3週；健康組不採取任何治療.分彆測定觀察組和對照組治療前後及健康組丙二醛(MDA)、血清晚期蛋白氧化產物(AOPPs)、血漿超氧化物歧化酶(SOD)和24h尿白蛋白排洩率(UAER).結果 對照組和觀察組治療前較健康組血漿MDA[(5.8 ±2.1)、(5.6±2.3) μmol/L比(3.8±0.9) μmol/L]、AOPPs[(69.4±10.9)、(69.2±11.1) μmol/L比(22.6±2.9) μmol/L]、24 h UAER[(274±33),(270±46) mg/24 h比(12 ±4) mg/24 h]明顯升高,SOD[(47±4)、(47±4)U/ml比(74±4) U/ml]較健康組明顯降低,差異均有統計學意義(均P＜0.05).對照組治療3週後MDA、AOPPs、SOD、24 h UAER與治療前比較差異無統計學意義(P＞0.05)；觀察組治療後MDA、AOPPs、24h UAER較治療前下降[分彆為:MDA為(2.7±1.9) μmol/L比(5.6±2.3) μmol/L,AOPPs為(61.7±12.6)μmol/L比(69.2±11.1) μmol/L],24 h UAER為(183±42) mg/24 h比(270±46) mg/24 h,SOD較治療前[(52±4)U/ml比(47±4) U/ml]升高,治療後各指標與治療前比較差異有統計學意義(P＜0.05).結論 氧化應激在糖尿病腎病的髮生髮展中起重要作用.α硫辛痠能降低糖尿病患者氧化應激水平,延緩糖尿病腎病進展.
목적 관찰항양화제α류신산대조기당뇨병신병환자양화응격수평적영향급대신장적보호작용.방법 채용수궤수자표장80례조기당뇨병신병환자수궤분위관찰조(40례)화대조조(40례),령종문진체검중심선택30례건강인위건강조.대조조급여상규치료；관찰조재상규치료적기출상가용α류신산0.6 g/차,1차/d정맥적주,료정3주；건강조불채취임하치료.분별측정관찰조화대조조치료전후급건강조병이철(MDA)、혈청만기단백양화산물(AOPPs)、혈장초양화물기화매(SOD)화24h뇨백단백배설솔(UAER).결과 대조조화관찰조치료전교건강조혈장MDA[(5.8 ±2.1)、(5.6±2.3) μmol/L비(3.8±0.9) μmol/L]、AOPPs[(69.4±10.9)、(69.2±11.1) μmol/L비(22.6±2.9) μmol/L]、24 h UAER[(274±33),(270±46) mg/24 h비(12 ±4) mg/24 h]명현승고,SOD[(47±4)、(47±4)U/ml비(74±4) U/ml]교건강조명현강저,차이균유통계학의의(균P＜0.05).대조조치료3주후MDA、AOPPs、SOD、24 h UAER여치료전비교차이무통계학의의(P＞0.05)；관찰조치료후MDA、AOPPs、24h UAER교치료전하강[분별위:MDA위(2.7±1.9) μmol/L비(5.6±2.3) μmol/L,AOPPs위(61.7±12.6)μmol/L비(69.2±11.1) μmol/L],24 h UAER위(183±42) mg/24 h비(270±46) mg/24 h,SOD교치료전[(52±4)U/ml비(47±4) U/ml]승고,치료후각지표여치료전비교차이유통계학의의(P＜0.05).결론 양화응격재당뇨병신병적발생발전중기중요작용.α류신산능강저당뇨병환자양화응격수평,연완당뇨병신병진전.
Objective To observe alpha-lipoic acid(ALA) oxidative stress levels in patients with early diabetic nephropathy and the influence of the renal protective effect.Methods Eighty early diabetic nephropathy patients were randomly divided into experimental group and control group with 40 cases in each group.In addition,30 healthy people were as a normal group.The control group was given elementary treatment; the experimental group was additionally given ALA 0.6 g by inrtavenous drip infusion once a day.Both treatments lasted for 3 weeks.The blood level of malondialdehyde (MDA),advanced oxidation protein products (AOPPs),super oxide dismutase (SOD) and 24 h urinary albumin excretion rate (UAER) were compared before and after treatment.Results The blood level of MDA [(5.8 ± 2.1),(5.6 ± 2.3) μmol/L vs (3.8 ± 0.9) μmol/L],AOPPs [(69.4 ± 10.9),(69.2 ± 11.1) μmol/L vs (22.6 ± 2.9) μmol/L],24 h UAER[(274 ± 33),(270 ± 46) mg/24 h vs (12 ± 4) mg/24 h]were significantly increased and the level of SOD [(47 ±4),(47 ±4) U/ml vs (74 ±4) U/ml]was obviously reduced (P ＜ 0.05) in both groups compared with normal control group before treatment.There were no sigificant differences in MDA,AOPPs,SOD,24 h UAER in the control group(P ＞ 0.05),but in experimental group MDA[(2.7 ±1.9) μmol/L vs (5.6 ±2.3)μmol/L],AOPPs[(61.7±12.6)μmol/L vs (69.2 ±11.1)μ mol/L],24 h UAER[(183 ±42) mg/24 h vs (270 ±46) mg/24 h] were significantly decreased and SOD[(52 ±4) U/ml vs (47 ±4) U/ml] was significantly increased(P ＜ 0.05) compared with before treatment.Conclusions Oxidative stress in diabetic nephropathy plays an important role in the development.ALA can reduce the level of oxidative stress in diabetes and slow the progress of diabetic nephropathy.
